Researchers use genome-wide CRISPR technology to identify leukemia's weakness

A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse.

We used CRISPR technology to carry out a genome-wide screen in leukemia cells to block thousands of genes at once. This is an extremely powerful tool that allowed us to identify a multitude of genes that fuel leukemia growth and find new vulnerabilities that can be targeted in this disease. The study also shows, for the first time, that whole genome CRISPR-based screens can in fact be carried out in a manner that is much more physiologically relevant: using primary cancer cells, and in the setting of the native microenvironment."

Tannishtha Reya, PhD, senior author, professor in the departments of Pharmacology and Medicine, University of California San Diego

Reporting in the April 20, 2020 online edition of the journal <a data-cke-saved-href="Nature Cancer, Reya and colleagues identified RNA-binding proteins -- which normally control how, when and if cells make certain proteins -- as a key class of proteins that sustain and protect drug-resistant leukemia stem cells. The authors focused on Staufen2 (Stau2), a relatively understudied member of the RNA-binding protein family that was previously only known to control brain and nervous system development.

This work was carried out in collaboration with UC San Diego investigators Gene Yeo, PhD, and Anjana Rao, PhD, and was conducted by lead author Jeevisha Bajaj, PhD, while she was a postdoctoral fellow at UC San Diego in the Reya lab. Bajaj subsequently joined the University of Rochester Medical Center as assistant professor of biomedical genetics and a researcher at the Wilmot Cancer Institute.

The team developed a mouse model in which Stau2 was genetically deleted and found that loss of this protein led to a profound reduction in leukemia growth and propagation, and markedly improved overall survival in mouse models. Stau2 was also required for continued growth of primary tissue samples of patients with leukemia, indicating a conserved dependence in the human disease.

"We are particularly excited about this work because, to our knowledge, this is the first demonstration that Staufen2 is a key dependency in any cancer," said Reya, who is a member of Moores Cancer Center and the Sanford Consortium for Regenerative Medicine.

To understand how Stau2 controls cancer, researchers undertook a genome-scale computational analysis of its targets through RNA-Seq and eCLIP-Seq. This led to the discovery that this protein controls key oncogenes, such as Ras, and epigenetic regulators, such as the LSD/KDM family of proteins, which are critical drug targets being tested against leukemia and other cancers.

According to the National Cancer Institute, approximately 1.5 percent of men and women will be diagnosed with leukemia at some point during their lifetimes. While chronic myeloid leukemia (CML) can be controlled with targeted therapies, this disease can be lethal if it advances or is diagnosed in an acute "blast" phase. The findings also have implications for acute myeloid leukemia (AML) and other blood cancers.

"This work will be particularly important for the discovery of new treatments," said Bajaj. "Our genome-wide screen identified cellular signals critical for the growth of cancer, and in the future, this study will be useful to study the microenvironment, the area around the tumor that includes tissue, blood vessels and important molecular signals related to how the cancer behaves."

Source:
Journal reference:

Bajaj, J., et al. (2020) An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia.  Nature Cancer. doi.org/10.1038/s43018-020-0054-2.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    UC San Diego. (2022, November 11). Researchers use genome-wide CRISPR technology to identify leukemia's weakness. AZoLifeSciences. Retrieved on November 13, 2024 from https://www.azolifesciences.com/news/20200421/Researchers-use-genome-wide-CRISPR-technology-to-identify-leukemias-weakness.aspx.

  • MLA

    UC San Diego. "Researchers use genome-wide CRISPR technology to identify leukemia's weakness". AZoLifeSciences. 13 November 2024. <https://www.azolifesciences.com/news/20200421/Researchers-use-genome-wide-CRISPR-technology-to-identify-leukemias-weakness.aspx>.

  • Chicago

    UC San Diego. "Researchers use genome-wide CRISPR technology to identify leukemia's weakness". AZoLifeSciences. https://www.azolifesciences.com/news/20200421/Researchers-use-genome-wide-CRISPR-technology-to-identify-leukemias-weakness.aspx. (accessed November 13, 2024).

  • Harvard

    UC San Diego. 2022. Researchers use genome-wide CRISPR technology to identify leukemia's weakness. AZoLifeSciences, viewed 13 November 2024, https://www.azolifesciences.com/news/20200421/Researchers-use-genome-wide-CRISPR-technology-to-identify-leukemias-weakness.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research reveals that pain-blocking neurotransmitters offer long-term relief in mice